Hutchinson Center study suggests HPV 18 may be useful for predicting prognosis of invasive cervical cancer

March 28, 2001

A strain of human papillomavirus called HPV 18, which is found in up to 30 percent of women with cervical cancer, appears to be associated with a mortality rate that's nearly double that of other HPV-related cervical cancers, according to a Fred Hutchinson Cancer Research Center study.

Results of the research, published today in the Journal of Clinical Oncology, confirm several previous, smaller studies that suggest HPV 18 may be an excellent molecular tumor marker for predicting the prognosis of women diagnosed with early-stage cervical cancer.

The National Cancer Institute-funded project, led by Stephen Schwartz, Ph.D., and colleagues, is the largest, most comprehensive and first population-based study to assess the viability of HPV 18 as a prognostic tumor marker for invasive cervical carcinoma.

"I think that the study potentially has very important clinical implications, as well as implications for new basic research," said Schwartz, an associate member of the Hutchinson Center's Public Health Sciences Division. "What is needed now is a trial to see if measuring the presence of HPV 18 in the tumors of cervical-cancer patients makes a difference in clinical outcome in terms of using this information to make treatment or monitoring decisions."

In other words, women with poorer prognosis, whose cervical tumors harbor HPV 18, perhaps could be treated more aggressively in the first place and monitored more frequently after initial treatment.

The findings also could impact the development of HPV vaccines for both treatment and prevention. "We don't know yet if such vaccines work, but if they do, there could be a trend toward patients getting their tumors tested to determine what strain of HPV is present, and then vaccinating them against that particular strain," said Schwartz, also an associate professor of epidemiology at the University of Washington School of Public Health and Community Medicine.

Human papillomavirus, a sexually transmitted disease that is the primary cause of cervical cancer, is present in virtually all cases of invasive cervical cancer. It is estimated that more than 6 million women in the United States are infected with HPV, of which there are more than 100 types. While all types can cause the growth of abnormal cells, usually only the high-risk variety - about a dozen of which so far have been identified - have been linked to cancer.

Schwartz and colleagues followed 399 women in western Washington with invasive cervical cancer at various stages. The women came from King, Pierce and Snohomish counties and were treated at a variety of hospitals. The women were followed for more than four years on average.

While the majority of these women tested positive for HPV 16 - the most common HPV strain linked to cervical cancer, accounting for about half of all cases - about 20 percent of the women in the study had HPV 18-related tumors. Adjusting for age, cancer stage and histological type, the risk of dying from cervical cancer was increased two-fold for patients whose tumors contained HPV 18 DNA compared to those whose tumors contained HPV 16 DNA.

The molecular mechanisms that cause HPV 18 to be associated with poor prognosis are unknown; basic research is needed to identify this link so new therapies can be developed to counteract this fast-growing, aggressive form of cervical cancer. Understanding these yet-to-be identified mechanisms, which may also be present at lower levels in other types of cervical cancer, could reduce deaths among all women with invasive cervical cancer.

"Although a tumor marker such as HPV 18 can be clinically valuable even when we don't know everything about what it does physiologically, knowing the mechanisms should maximize our ability to design treatments to counteract the marker's effect," Schwartz said.
Editor's note: A copy of the paper "Human Papillomavirus and Prognosis of Invasive Cervical Cancer: A Population-Based Study" Vol. 19, No. 7, pp. 1906-1915, 2001 can be obtained by calling the journal at 703-299-1016.

The Fred Hutchinson Cancer Research Center is an independent, nonprofit research institution dedicated to the development and advancement of biomedical technology to eliminate cancer and other potentially fatal diseases. Recognized internationally for its pioneering work in bone-marrow transplantation, the Center's four scientific divisions collaborate to form a unique environment for conducting basic and applied science.

The Hutchinson Center is the only National Cancer Institute-designated comprehensive cancer center in the Pacific Northwest. For more information, visit the Center's Web site at Advancing Knowledge, Saving Lives

Fred Hutchinson Cancer Research Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to